Skip to main content
Premium Trial:

Request an Annual Quote

XDx Raising Private Cash After Pulling IPO

SAN FRANCISCO (GenomeWeb News) – Molecular diagnostics firm XDx has started the process of raising cash through a round of private financing just a few months after pulling its planned initial public offering.

XDx President and CEO Pierre Cassigneul said Tuesday at the JPMorgan Healthcare Conference held here that the firm is aiming to raise between $21 million and $25 million in a final private round of financing that it expects to close in the first half of 2010. Those funds will help the firm realize its goal of breaking even in 2010, Cassigneul said.

Also helping the firm achieve that goal is a recent restructuring, which includes cutting 25 staff positions. XDx announced the restructuring in November and said that it would undertake "other cost-saving measures" that are expected to speed the firm's path to profitability, but it did not provide further details regarding those other measures.

At the time, Brisbane, Calif.-based XDx said that it would shift its priorities to efforts that will increase research, development, and commercial activities in support of its AlloMap test for management of heart transplant patients. The firm also intends to continue "selected activities" in autoimmunity.

On Tuesday, Cassigneul said that the firm has two major studies ongoing. The first is comparing the AlloMap test with endomyocardial biopsy. The second is for identifying biomarkers and molecular pathways involved in lupus. The company hopes to eventually sell two tests for lupus – one which will be used for risk stratification and a second that would be used as a predictor of lupus flare-up.

Filed under

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.